Zeo ScientifiX, Inc. (ZEOX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001557376 0001557376 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earl
How this was made
The 30-second read
Why it matters
This disclosure updates the equity compensation stack (who received options, vesting structure, cashless exercise, strike price, and an antidilution feature tied to future issuances).
Market read
Traders may reassess dilution/overhang and insider alignment, but there is no new operational or financial catalyst beyond the option terms.
What to watch
The filing specifies antidilution for certain future issuances (10%+ fully diluted), which may matter for how investors model future financing and dilution mechanics.
Background
The company filed an 8-K under Item 5.02 describing director/officer changes and compensatory arrangements, specifically option grants under its 2021 Incentive Stock Plan.
Ticker impact
Zeo ScientifiX granted fully vested and performance-milestone stock options to CEO/CFO Ian Bothwell, CMO George Shapiro, and a consultant/stockholder Greyt Ventures at a $1.67 strike.
Likely limited immediate price impact; watch for follow-through if investors interpret the awards as confidence in performance milestones or as dilution/overhang risk.
The filing is a primary SEC disclosure of equity compensation terms, but it does not include new financial guidance, clinical/product catalysts, or a transaction that directly changes fundamentals.
Market effects
For micro/small-cap biotech/healthcare issuers, option-heavy compensation structures can influence perceived governance and dilution risk, but no sector-wide regulatory/clinical signal is provided here.
None indicated.
None indicated.
Counterpoint
The fully vested options and cashless exercisability could be viewed as supportive of retention/alignment rather than dilution risk, especially if performance milestones are credible.
Key entities
- issuerZeo ScientifiX, Inc.
Granted stock options under its 2021 Incentive Stock Plan to CEO/CFO Ian Bothwell, CMO George Shapiro, consultant/stockholder Greyt Ventures LLC, and non-executive director Chuck Bretz.
